SKINBIOTHERAPEUTICS PLC
Get an alert when SKINBIOTHERAPEUTICS PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-12-31 (in 7mo)
Last filed for 2025-06-30
Confirmation statement due
2026-06-24 (in 1mo)
Last made up 2025-06-10
Watchouts
Cash
£5M
+496.8% vs 2024
Net assets
£9M
+217.2% vs 2024
Employees
34
+142.9% vs 2024
Profit before tax
-£715K
+75.7% vs 2024
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Outstanding charges registered
One or more mortgages or charges remain undischarged on the Companies House register.
-
5 officer resignations in last 12 months
Multiple officers have left the board recently — see the People section for who.
Net assets
2-year trend · vs Health Care median
Accounts
2-year trend · latest reflected 2025-06-30
| Metric | Trend | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Turnover | £1,208,669 | £4,638,147 | |
| Operating profit | -£2,905,132 | -£1,123,135 | |
| Profit before tax | -£2,948,892 | -£715,116 | |
| Net profit | -£2,875,990 | -£696,253 | |
| Cash | £800,904 | £4,779,433 | |
| Total assets less current liabilities | £3,410,366 | £10,656,475 | |
| Net assets | £2,969,881 | £9,419,097 | |
| Equity | £2,969,881 | £9,419,097 | |
| Average employees | 14 | 34 | |
| Wages | £922,275 | £1,135,461 | |
| Directors' remuneration | £761,311 | £746,501 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2024 → FY2025 · period ending 2025-06-30 vs 2024-06-30
-
Turnover
+283.7%
£1,208,669 £4,638,147
-
Cash
+496.8%
£800,904 £4,779,433
-
Net assets
+217.2%
£2,969,881 £9,419,097
-
Employees
+142.9%
14 34
-
Operating profit
+61.3%
-£2,905,132 -£1,123,135
-
Profit before tax
+75.7%
-£2,948,892 -£715,116
-
Wages
+23.1%
£922,275 £1,135,461
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating margin | -240.4% | -24.2% | |
| Net margin | -237.9% | -15.0% | |
| Return on capital employed | -85.2% | -10.5% | |
| Gearing (liabilities / total assets) | 43.1% | 22.3% | |
| Current ratio | — | 4.84x | |
| Interest cover | -66.39x | -12.21x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 2 times since incorporation
- SKINBIOTHERAPEUTICS PLC 2016-12-23 → present
- SKINBIOTHERAPEUTICS LTD 2016-12-23 → 2016-12-23
- SKINBIOTIX LTD 2015-06-10 → 2016-12-23
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- Gravita Audit II Limited
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“the Directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Accordingly, they continue to adopt the going concern basis in preparing the annual report and financial statements.”
Group structure
- SKINBIOTHERAPEUTICS PLC · parent
- SkinBiotix™™™™ Limited 100%
- AxisBiotix Limited 100%
- MediBiotix Limited 100%
- CleanBiotix Limited 100%
- PharmaBiotix Limited 100%
- Dermatonics Limited 100%
- Bio-Tech Solutions Limited 100%
Significant events
- “Just before the year end, we signed an exclusive agreement with Superdrug around AxisBiotix™™™ and post year end, stock was placed on High Street shelves for consumers.”
- “Our first acquisition, Dermatonics, occurred in January 2024 with a second, Bio-Tech Solutions, taking place in October 2024.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
6 active · 11 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BERTRAM, Emily Lorraine | Secretary | 2025-05-31 | — | — |
| BERTRAM, Emily Lorraine | Director | 2026-01-01 | Sep 1983 | British |
| HUNT, Martin Braddock | Director | 2016-10-03 | Dec 1958 | British |
| LEVETT, Alyson Margaret | Director | 2026-01-01 | Jan 1966 | British |
| PARSONAGE, Rachel Lisa | Director | 2026-03-09 | Dec 1974 | British |
| PRESCOTT, Catherine Denise, Dr | Director | 2017-03-01 | Apr 1961 | British |
Show 11 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| COLLINGBOURNE, Mark Kingsley | Secretary | 2016-01-19 | 2017-01-13 |
| QUINN, Doug | Secretary | 2017-01-14 | 2022-06-01 |
| RANDHAWA, Manprit Singh | Secretary | 2022-06-01 | 2025-05-31 |
| ASHMAN, Stuart | Director | 2019-04-18 | 2026-02-13 |
| BEKKER, Danielle | Director | 2022-04-27 | 2025-12-31 |
| HEWITSON, Simon Jonathan | Director | 2025-04-28 | 2025-10-14 |
| LAIRD, Robert James Taylor | Director | 2016-03-17 | 2016-12-22 |
| O'HARA, Stephen Patrick | Director | 2015-06-10 | 2019-07-04 |
| O'NEILL, Catherine Anne, Dr | Director | 2016-03-17 | 2019-07-04 |
| QUINN, Douglas John | Director | 2016-12-22 | 2022-06-01 |
| RANDHAWA, Manprit Singh | Director | 2022-06-01 | 2025-05-31 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Optibiotix Health Plc | Corporate entity | Shares 25–50%, Voting 25–50% | 2017-07-24 | Ceased 2020-11-02 |
Filing timeline
Last 20 of 98 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-01-08 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-04-13 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2026-03-09 | AP01 | officers | Appoint person director company with name date | |
| 2026-02-13 | SH01 | capital | Capital allotment shares | |
| 2026-02-13 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-26 | SH01 | capital | Capital allotment shares | |
| 2026-01-08 | AP01 | officers | Appoint person director company with name date | |
| 2026-01-08 | TM01 | officers | Termination director company with name termination date | |
| 2026-01-08 | AP01 | officers | Appoint person director company with name date | |
| 2026-01-08 | RESOLUTIONS | resolution | Resolution | |
| 2025-12-16 | AA | accounts | Accounts with accounts type group | |
| 2025-10-14 | TM01 | officers | Termination director company with name termination date | |
| 2025-07-01 | SH01 | capital | Capital allotment shares | |
| 2025-06-13 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-06-09 | TM02 | officers | Termination secretary company with name termination date | |
| 2025-06-09 | AP03 | officers | Appoint person secretary company with name date | |
| 2025-06-09 | TM01 | officers | Termination director company with name termination date | |
| 2025-05-13 | AP01 | officers | Appoint person director company with name date | |
| 2025-05-02 | SH01 | capital | Capital allotment shares | |
| 2025-04-08 | SH01 | capital | Capital allotment shares | |
| 2025-04-01 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 18
- Capital events
- 6
- Officers appointed
- 4
- Officers resigned
- 5
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.